Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin With Rapamycin Plus Tacrolimus in Liver Transplant Patient

Transplantation Proceedings

Volumn 41, Issue 3, 2009, Pages 1021-1024

  Dopazo, C ^a   Bilbao, I ^a   Lazaro J L ^a   Sapisochin, G ^a   Caralt, M ^a   Blanco, L ^a   Castells, L ^b   Charco, R ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG WITHDRAWAL; GRAFT REJECTION; HEART VENTRICLE FIBRILLATION; HEMODIALYSIS; HEPATITIS C; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHABDOMYOLYSIS;

ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HEPATITIS C; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, ACUTE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; RHABDOMYOLYSIS; SIMVASTATIN; TACROLIMUS;

EID: 64349118448     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.02.019     Document Type: Article

References (31)

1. Busuttil R.W., Douglas G.T., Hassan Y., et al. Analysis of long term outcomes of 3,200 liver transplantations over two decades. A single-center experience. Ann Surg 241 (2005) 905
2. Fellstrom B. Impact and management of hyperlipidemia post-transplantation. Transplantation 70 11 suppl (2000) SS51
3. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 7 (2001) S13
4. Jindal R.M., Sidner R.A., Hughes D., et al. Metabolic problems in recipients of liver transplants. Clin Transplant 10 (1996) 213
5. Moore R., Hernandez D., and Valantine H. Calcineurin inhibitors and post-transplant hyperlipidaemias. Drug Saf 24 (2001) 755
6. Kahan B.D., and Rapamune study group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection. Lancet 356 (2000) 194
7. Kniepeiss D., Iberer F., Schaffellner S., et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 18 (2004) 642
8. Williams D., and Freely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41 (2002) 343
9. Bellosta S., Paoletti R., and Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 (2004) 50
10. Wratchford P., and Ponte C.D. High dose simvastatin and rhabdomyolysis. Am J Health Syst Pharm 60 (2003) 698
11. Neal D.A.J., Tom B.E.M., Luan J., et al. Is there a disparity between risk and incidence of cardiovascular disease after liver transplant?. Transplantation 77 (2004) 93
12. Johnston S.D., Morris J.K., and Cramb R. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73 (2002) 901
13. Abtahi P., and Zand M.S. Management of hyperlipidemia in the stable solid organ transplant recipient. Graft 4 (2001) 266
14. Ucar M., Mjorndal T., and Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22 (2000) 441
15. Bays H., and Dujovne C.A. Drug interactions of lipid-altering drugs. Drug Saf 19 (1998) 355
16. Asberg A. Interactions between cyclosporine and lipid-lowering drugs. Implications for organ transplant recipients. Drugs 63 (2003) 367
17. Schmidt G.A., Hoehns J.D., Purcell J.A., et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 20 (2007) 411
18. Schech S., Graham D., Staffa J., et al. Risk factors for statin associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 16 (2007) 352
19. Jacobson T.A., and Zimmerman F.H. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens 8 (2006) 35
20. Thompson P.D., Clarkson P., and Karas R.H. Statin associated myopathy. JAMA 289 (2003) 1681
21. Martin J.E., Cavanaugh T.M., Trumbull L., et al. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant 22 (2008) 113
22. Shek A., and Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother 35 (2001) 909
23. Fontana I., Ginervi F., Basile G., et al. Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody. Transplant Proc 36 (2004) 711
24. Patel D.N., Pagani F.D., Koelling T.M., et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant 21 (2002) 204
25. Turk S., Yildez A., Tukek T., et al. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study. Int Urol Nephrol 32 (2001) 713
26. Keogh A., Macdonald P., Kaan A., et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 19 (2000) 529
27. Magnani G., Carini V., Magelli C., et al. Role of statin in the management of dyslipidemia after cardiac transplant: randomized, controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant 19 (2000) 710
28. Santos A.F., Keitel E., Bittar A.E., et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double blind, randomized, placebo-controlled study. Transplant Proc 33 (2001) 1194
29. Najafian B., Franklin D.B., and Fogo A.B. Acute renal failure and myalgia in a transplant recipient. J Am Soc Nephrol 18 (2007) 2870
30. Zachoval R., Gerbes A.L., and Pahrhofer K.G. Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized crossover trial. J Hepatol 35 (2001) 86
31. Mikkelsen T.S., and Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand 49 (2005) 389